AMGN Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
About Amgen (NASDAQ: AMGN)
›
Amgen (NASDAQ: AMGN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 31,500 employees.
The shares were at 438.82 USD on 19 November 2026, up 42.1% over 52 weeks. Its 52-week range is 312.39 USD to 483.99 USD: the price is 9.3% below the high and 40.5% above the low.
At a market capitalisation of 237.36B USD, it trades at 25.4 times trailing earnings and 17.5 times forward earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 26.0, so AMGN is valued in line with them. It pays a dividend yielding 2.27% (it pays out 58% of its earnings), against a median of 2.55% among the dividend payers in that peer group.
Amgen reports return on equity of 89.1%, an operating margin of 34.1% and revenue up 8.5% year over year.
Its debt exceeds its cash by 40.82B USD, a debt-to-equity ratio of 6.31. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 29 analysts cover the stock, with an average rating of Hold; their mean price target of 435.77 USD is 0.7% below the current price. The next earnings report is expected on 2 February 2027.